Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

G. Steven Burrill Issues Annual Predictions for the Biotechnology Industry

GlobeNewswire December 16, 2014

International Stem Cell Corporation Ranked as One of America's Fastest Growing Companies by Deloitte

Marketwired December 16, 2014

AncestryDNA Reconstructs Partial Genome of Person Living 200 Years Ago

GlobeNewswire December 16, 2014

Alimera Sciences Added to NASDAQ Biotechnology Index

PR Newswire December 16, 2014

Kite Pharma Added to the NASDAQ Biotechnology Index

GlobeNewswire December 16, 2014

Atossa Genetics Inc. Hires Pieter van der Poel as Vice President of European Commercial Operations

Marketwired December 16, 2014

Magnolia Solar Recipient of US Patent on High-Efficiency Multi-Junction Solar Cells

GlobeNewswire December 16, 2014

Relypsa Announces Stephen D. Harrison, M.A., Ph.D., Joins as Senior Vice President and Chief Scientific Officer

GlobeNewswire December 16, 2014

Celladon Corporation Added to NASDAQ Biotechnology Index

GlobeNewswire December 16, 2014

CombiMatrix Launches Targeted Array for Prenatal Analysis

GlobeNewswire December 16, 2014

Retrophin Announces Addition to the NASDAQ Biotechnology Index

Business Wire December 16, 2014

ZS Genetics, Inc., Developer of a Unique and Potentially Disruptive "Third-Generation" DNA Sequencing Technology Platform, Announces Organization Change to Accelerate Strategic Plans

Business Wire December 16, 2014

Meningococcal Meningitis Survivor and TV Personality Amy Purdy and Pfizer Launch Take Action Against Meningitis

Business Wire December 16, 2014

Major Breakthrough for Lymphoma Patients: What If You Could Live Five More Years?

Canada NewsWire December 16, 2014

Cancer Genetics, Inc. Announces Appointment of Venkatadri Bobba to Cancer Genetics India's Board of Directors

GlobeNewswire December 16, 2014

Applied DNA Sciences Reports Fiscal Year End 2014 Results

Marketwired December 16, 2014

Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis

GlobeNewswire December 16, 2014

Zafgen Added to NASDAQ Biotechnology Index

GlobeNewswire December 16, 2014

Brian C. Wilson Joins Theralase Medical and Scientific Advisory Board

TheNewsWire December 16, 2014

CMC Biologics and OncoSynergy Enter into an Agreement for Accelerated Process Development and GMP Manufacture of an Investigational Drug to Combat Ebola

PR Newswire December 16, 2014